Dear Editor,

Facing a new threat, healthcare workers (HCW) have joined a major task force worldwide to fight the COVID-19 caused by an emerging coronavirus related to a severe acute respiratory syndrome, named SARS-CoV-2. The new betacoronavirus led to disease outbreaks worldwide and posed several challengers to the global public health. Due to the severity and the potential of spreading on an international scale, the WHO declared it a pandemic situation in March 2020.[@bib1] SARS-CoV-2 infection may be mainly related to fever, fatigue, and dry cough and, in severe cases, pneumonia, acute respiratory syndrome leading, sometimes, to death. However, considering immunopathological aspects, about 80% of patients with SARS-CoV-2 infection might experience mild or null symptoms.[@bib2] As with other respiratory pathogens, the virus may be transmitted from human-to-human, and symptomatic people are the most frequent source of COVID-19. Transmission occurs through respiratory droplets and aerosol from coughing and sneezing. Social distancing and patient isolation are still the best way to contain and fight this pandemic.[@bib3]

Overall, considering this disease complexity and the lack of deep understanding of its pathophysiology, the health of HCW is of special significance given the possibility of them to get infected on duty. In a situation of personnel loss, the consequences would go beyond to one more infected, but may impact the near to, or collapsed health system. At first, it would be valid to assume that the remission of symptoms, in symptomatic cases, associated with negative tests or baseline detection of antibodies, would be decisive for the professional\'s return to work. In this context, an active Brazilian physician, at primary care service, tested non-reactive for COVID-19 in serological tests after returning to work. She was previously tested positive for SARS-CoV-2 by RT-qPCR and underwent 14 days of quarantine. In fact, this situation is of importance given that a middle-income country, such as Brazil, must count with every HCW to fight a still growing number of COVID-19 victims including more than 85,000 deaths between March and July 2020. The physician is a healthy 26-years-old female and did not fall in any group of risks for COVID-19. She reported, initially (day 1), runny nose (nasal discharge) on May 2nd, and progressed to additional symptoms which included sore throat, runny nose, dry cough, body ache and weakness. On the third day, she was submitted to the collection of nasal and oropharyngeal swabs for which the tests came out positive. The tests were run in duplicate in two independent experiments following the Center for Disease Control and Prevention\'s 2019-Novel Coronavirus RT-qPCR Diagnostic Panel.[@bib4]

After complete remission of symptoms and quarantine period, the HCW got back to work in the primary care service on day 16. Following a monitoring protocol for HCW after COVID-19, she was submitted to serology on day 26 and the results came out non-reactive for anti-SARS-CoV-2 IgG. The test was repeated four days later (June 2nd) in a different laboratory and different methodological approaches (chemiluminescence and immunofluorescence). After another 14 days (June 16th), she underwent a set of more detailed tests to assess her actual health condition and search for any immunodeficiency that could interfere with post-COVID-19 serology. At this time, anti-SARS-CoV-2 IgG and anti-HIV-1/HIV-2 serology were performed, in addition to IgG subclasses, Complement C3 and C4, screening for TCD3+, TCD4+, TCD8+ and BCD19+. Erythrogram, leukogram, platelets evaluation, urea and glucose were also performed. A timeline summarization and laboratory test results are presented in [Fig. 1](#fig1){ref-type="fig"} . Overall, no alterations were detected in any of the tests performed. The HCW showed to be in good health conditions and no signs of immunodeficiency were observed.Figure 1Timeline summarization for the case-related events (A) and detailed information on laboratory tests and reference values (B).Fig. 1

It is incredibly important to address the potential responses of the human immune system during the SARS-CoV-2 infection. Humoral immune response, especially the production of neutralizing antibody, plays a protective role by limiting the infection at a later phase and prevents re-infection in the future, although controversial information is observed in the literature with regards COVID-19.[@bib1] Not all patients may develop classic response based on neutralizing antibodies, but instead, T cells seems to play an important protective role in individuals with asymptomatic or mild disease. In this direction, it is suggested that with regards to SARS-CoV-2, specific T cells have already been identified, but it is still unclear to what extent the T cell response associate with COVID-19. As for COVID-19 pathogenesis, the pattern of immunodominance may differ for other coronaviruses.[@bib5] Apart from both social and scientific relevance of this topic, further prospective studies are needed to better address immunological aspects of COVID-19. In deep, horizontal comparisons are difficult as methodological approaches may significantly differ in earlier studies.
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